Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

The Health Insurance Store Joins AmeriLife’s Insurance Services LLC Partners

AmeriLife

Insurance Services LLC, a national distributor of Medicare Advantage and Medicare Supplement solutions and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has partnered with The Health Insurance Store. Led by Owner and President Aaron Zolbrod, The Health Insurance Store is an independent insurance agency specializing in Medicare solutions as well as group, family and individual health insurance plans. Per the agreement, terms of the deal were not disclosed. "Today’s announcement marks an exciting milestone for The Health Insurance Store and our team of passionate, dedicated insurance specialists,” said Zolbrod. “We’re excited to continue our journey with Insurance Services LLC as part of AmeriLife, and look forward to the many possibilities that lie ahead for us and our clients." Founded in 2008 and headquartered outside of Pittsburgh in Connellsville, Penn., The Health Insurance Store has helped more than 10,000 active clients across western Pennsylvania not only better understand their health insurance needs but deliver them the best, most cost-effective coverage. The firm is a long-standing partner of Insurance Services LLC. Now, coupled with access to AmeriLife’s best-in-class technology, resources and distribution platform along with Insurance Service LLC’s continued support, The Health Insurance Store is poised to accelerate its growth across the region. "Aaron has been our partner for more than a decade. He runs a remarkable shop with an exceptionally dedicated client base,” said Larry Mikolajcik, CEO of Insurance Services LLC. “I’m excited to have them alongside us in our partnership with AmeriLife and look forward to supporting their growth for years to come.” “We’re thrilled to have The Health Insurance Store join AmeriLife’s family of companies,” added Mike Vietri, AmeriLife’s Chief Distribution Officer. “With energetic leadership at the helm and a strong team of tenured, performative agents, The Health Insurance Store is poised for continued success. We look forward to helping them along their journey.” ### About The Health Insurance Store The Health Insurance Store, headquartered in Connellsville, Penn., is an independent insurance agency specializing in Medicare solutions and individual, family and group health insurance plans. Founded in 2008 with offices in Pennsylvania and New Mexico, the agency is known as the “Home of the Medicare Specialists,” and has provided guidance and support to more than 10,000 clients to help them save money and better understand their health care. For more information on The Health Insurance Store, visit GetYourBestPlan.com. About Insurance Services LLC Founded in 1980, Insurance Services LLC is a family-owned and operated insurance marketing organization that primarily distributes Medicare Advantage and Medicare Supplement products. The firm, which is headquartered in Greensburg, Penn., has more than 300 licensed agents that deliver “satisfaction through service” to Medicare-eligible beneficiaries nationwide. For more information, visit MyInsuranceTeam.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

November 17, 2022 09:00 AM Eastern Standard Time

OTCMKTS : $OCEL 📋 Organicell Activates COPD Trial at Mayo Clinic!

Organicell Regenerative Medicine, Inc.

Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/

November 16, 2022 01:20 PM Eastern Standard Time

Video

How To Win At Holiday Hosting: Everything You Need to Know When Hosting Family & Friends

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/DmvrRaRjo4E November officially ushers in the holiday season, bringing with it the hustle and bustle we’ve been missing the past couple of years. Registered Dietitian Nutritionist, Mia Syn says there are a few easy ways to win at hosting while setting the scene for all the fun, food, and festivities. PLAN THE MENU AHEAD OF TIME: This holiday season is expected to be as “back to normal” as possible after more than two years of restrictions. For those taking on the role of hosting, Syn admits it could be a little nerve-racking, “That’s why I recommend planning the menu ahead of time, including main dishes, drinks, desserts, and the overall presentation.” The Registered Dietician Nutritionist suggests kicking things off with an overflowing charcuterie board filled with a mixture of colors, textures, and flavors, including a variety of cheeses, meats, and lots of veggies. Syn says to make sure to include almonds, adding, “Look for flavors that will surprise your guests, but also help add a seasonal taste.” This year, Blue Diamond Almonds released its first-ever limited-time offer holiday flavored almonds. “They’re perfect for a seasonal charcuterie board or sharing as a gift or stocking stuffer. Your family will love the Blue Diamond Snickerdoodle Flavored Almonds. They have the delicious taste of a seasonal cinnamon sugar cookie… so good! And one of my favorites is the Peppermint Cocoa Flavored Almonds with a delicious chocolatey flavor and hint of peppermint.” These products are available at grocery stores nationwide and Amazon.com. Consumers can also use Blue Diamond’s product locator tool to find a nearby store. https://www.bluediamond.com/naughty-and-nice Facebook: www.facebook.com/BlueDiamondAlmonds/ Instagram: www.instagram.com/BlueDiamond Twitter: www.twitter.com/BlueDiamond DESSERTS WITH ADDED BENEFITS: A menu would not be complete without dessert. It may be a surprise, but Syn is a self-proclaimed “desserts girl,” saying, “I’m always about the desserts and this year I have a couple originals that are on the healthy side and taste fantastic!” She recommends a classic with a twist, blondies. “Believe it or not, my version is made with beans,” says Syn. The registered dietician nutritionist admits it may seem odd at first, but, “When cooked and rinsed well, beans can add moisture and fudginess to baked goods like brownies and blondies while cutting back on the amount of fat and flour needed. Not only that, but beans add nutrients such as plant protein, B vitamins, and fiber, making this a dessert with benefits.” Another option are Syn’s banana-sweetened chocolate chip oatmeal cookies. They’re made with a ripe banana mash, creamy peanut butter, quick oats, pure vanilla and dark chocolate chips. “There is also another surprise, these treats are made without flour, eggs, or added sugar,” says Syn. STOP DOING DISHES: Syn admits the menu building and preparation could be fun, but the cleanup is often taxing and takes up a lot of time. That’s why she suggests eliminating the time suckers, which includes washing dishes and loading the dishwasher. “We all know it takes time away from what’s really important. This time of year is so busy and should be spent on special traditions, making new memories, and being with the ones you love.” The Chinet® brand is focused on making cleanup easier so families can spend more time together. She says these products are made for exactly what’s on your menu, like a traditional honey-glazed turkey, or an old-fashioned ham with brown sugar and mustard glaze. For a more upscale affair, Syn suggests using the Chinet Crystal® products, which add a fancy touch to meals, perfect for a beef tenderloin, seared duck, or lamb with garlic and rosemary,” adding, “The crystal cups are great for that pre-dinner toast!” Most importantly, when partygoers are done eating dinner or dessert, Syn says, “Just toss the dishes and have all that extra time for family fun.” For more information, visit mychinet.com. Facebook: Facebook.com/mychinet Instagram: Instagram.com/mychinet Twitter: Twitter.com/mychinet Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 16, 2022 10:05 AM Eastern Standard Time

Video

AmeriLife’s Insurance Services LLC Partners with Insurance Services of Zelienople

AmeriLife

Insurance Services LLC, a national distributor of Medicare Advantage and Medicare Supplement solutions and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has partnered with Insurance Services of Zelienople. Led by owners Steve Schultz and Rachael Kirschner, Insurance Services of Zelienople is a leading, independent insurance agency specializing in life and health solutions focused in the Pennsylvania market. Per the agreement, terms of the deal were not disclosed. "We’re excited about joining AmeriLife because, first and foremost, it protects the future of our employees and our agents and their clients as our industry continues to change,” said Schultz and Kirschner in a joint statement. “Likewise, it continues our long-standing partnership with Insurance Services LLC, which has been extremely supportive of our growth for more than 40 years. Together, we will share success for years to come." As one of the premier, full-service independent health insurance brokerages in western Pennsylvania, Insurance Services of Zelienople has more than 50, dedicated first and second-generation career agents providing Medicare, prescription drug plans, and other health solutions to the fast-growing under-65 market. The firm is a 40-year-plus affiliate of Insurance Services LLC located in Greenburg, Penn., and together, they have provided their clients access to solutions from some of the top regional and national carriers. Now, as a member of the AmeriLife family of companies, Insurance Services of Zelienople joins a best-in-class distribution that will fuel its growth and help it expand its offerings. "Steve and Rachael have been a part of the Insurance Services family for many years, with Steve being one of my first five agents more than 40 years ago,” said Larry Mikolajcik, CEO of Insurance Services. “It’s been a privilege watching their success over the years, and their future remains bright. I’m grateful that Insurance Services of Zelienople will remain in the family and join us in our partnership with AmeriLife." “It’s extremely rare to see a partnership span more than four decades, let alone one as successful as the one between these two agencies,” added Mike Vietri, AmeriLife’s Chief Distribution Officer. “We couldn’t be more excited to welcome Insurance Services of Zelienople to AmeriLife’s industry leading distribution, and look forward to helping them help more clients live longer, healthier lives.” ### About Insurance Services of Zelienople Insurance Services of Zelienople is one of the premier independent health insurance brokerages in western Pennsylvania and Ohio. The firm specializes in Medicare Advantage, Medicare Supplement and prescription drug plans, as well as a variety of other solutions for the under-65 health insurance market. Founded by Steve Schultz in 1980, the family-owned and operated agency includes an expert team of more than 50 first and second-generation agents dedicated to delivering exceptional client service. For more information, visit ZelieInsurance.com. About Insurance Services LLC Founded in 1980, Insurance Services LLC is a family-owned and operated insurance marketing organization that primarily distributes Medicare Advantage and Medicare Supplement products. The firm, which is headquartered in Greensburg, Penn., has more than 300 licensed agents that deliver “satisfaction through service” to Medicare-eligible beneficiaries nationwide. For more information, visit MyInsuranceTeam.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

November 16, 2022 09:00 AM Eastern Standard Time

IBM and Algorithmiq join forces to pave the way toward useful quantum advantage for quantum chemistry

Algorithmiq

Algorithmiq, a Helsinki-based quantum computing startup, has entered into an engagement with IBM to progress in its exploration of quantum algorithms that attempt to solve complex issues in life sciences. This collaboration brings together IBM's world-leading hardware, software and quantum applications expertise with Algorithmiq's cutting-edge algorithm developers, to explore ways to dramatically cut the time and cost of drug discovery and development. The work will also contribute any work produced to Qiskit, an open-source SDK for quantum computers, with the aim of promoting and developing this nascent ecosystem. As part of the engagement, Algorithmiq will become part of the IBM Quantum Network. IBM’s researchers are collaborating with Algorithmiq to address how to overcome the main bottlenecks in today’s noisy quantum hardware, such as limited speed, accuracy, and scale, for large quantum chemistry simulations. Algorithmiq’s novel measurement techniques have shown to greatly reduce runtime in hybrid quantum-classical algorithms. In addition, Algorithmiq’s post-processing strategies for error mitigation have shown to significantly improve the accuracy of quantum chemistry simulations. Therefore, this collaboration looks to yield promising results to boost the performance of quantum algorithms on near-term quantum technology. Founded by a team of world-leading academics in the field, Algorithmiq is focused on leveraging the power of quantum computing so that new drugs can be explored and eventually brought to market, and cost-effectively, leading to precise medical treatments. On average, it currently takes around a decade and $1 billion for a new drug to get to market. Algorithmiq's advances are estimated to reduce the time-to-market of new, more efficient and less harmful drugs, significantly. Algorithmiq's mission is to prevent and cure diseases by exploiting the power of quantum computing combined with a complex systems approach to drug discovery and development. Sabrina Maniscalco, CEO and co-founder of Algorithmiq: “We are delighted to collaborate with IBM as we look to combine our world-leading quantum algorithms with IBM’s best-in-class hardware and quantum chemistry expertise toward realising the full potential of the technology for quantum chemistry simulations. Quantum computing holds the key to revolutionising the process of drug discovery and development. We couldn’t be more thrilled to be collaborating with a giant of the technology industry in our pursuit of this mission, placing ourselves at the forefront of innovation and the race to prove useful quantum advantage in the space.” Guillermo Garcia Perez, CSO and co-founder of Algorithmiq: “ Whilst unleashing the full power of quantum simulations will likely require fault-tolerant quantum computers, near-term devices like those developed by IBM, combined with our novel algorithms based on informationally complete data, are today already showing progress toward the demonstration of a quantum advantage for chemistry. This is a steppingstone for any application of quantum computers to Life Sciences.” Ivano Tavernelli, Global Leader for Advanced Algorithms for Quantum Simulations, IBM Research: “IBM believes the demonstration of quantum advantage in areas such as quantum chemistry is possible this decade. So, we are excited to collaborate with Algorithmiq in our efforts to push the industry forward, and we are glad to see the promising results they have achieved to date in improving the performance of near-term quantum algorithms. We are glad to support Algorithmiq’s ambition through the IBM Quantum Network, and believe that the company’s work could be pivotal in carving a path towards demonstrating quantum advantage with near-term quantum algorithms.” About Algorithmiq Algorithmiq develops software and quantum algorithms to solve complex issues in life sciences, with the mission to significantly reduce the time and cost it takes for pharma companies to bring new drugs for diseases to market. Based in Helsinki, the company is led by a team of ambitious, world-leading academics in quantum computing and is one of the only software companies specifically focused on optimising algorithms for NISQ to impact the drug discovery pipeline. In February 2022, the startup announced a $4m seed round backed by investment from Tiger Global, K5 Global and numerous angel investors. Alongside Co-Founder and CEO Professor Sabrina Maniscalco on Algorithmiq’s Board are:- Co-Founder and DeepMind advisor Dr Jussi Westergren; Jorma Ollila, former CEO and Chairman of Nokia; and Haakon Overli, founding General Partner at Dawn Capital, who sit on the board. About IBM For more information, visit https://www.ibm.com/quantum Contact Details Algorithmiq Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://algorithmiq.fi/

November 16, 2022 06:00 AM Eastern Standard Time

Image

AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials

AiViva BioPharma

If you would like to learn more about AiViva, check out its website. Visit https://www.startengine.com/aiviva to invest in AiViva’s StartEngine Campaign. Wet age-related macular degeneration, also known as wet AMD, is a chronic eye disorder that causes blurred vision or blind spots in the visual field of the eye. It’s caused by abnormal blood vessels that leak fluid or blood into the eye’s macula and scar it (the macula is the area of the eye that provides the sharp, central vision needed for reading, driving and seeing fine detail). Wet AMD can progressively lead to vision loss resulting in permanent blindness if left untreated, according to report s. Over 45% of patients on current therapies do not achieve meaningful vision gain. Currently there is no cure for wet AMD. Currently available treatment for wet AMD involves frequent injections in the eye. It can be a drawn-out process that takes anywhere from four to 12 weeks so new product development for wet AMD is focused on developing longer-acting effective drugs, which could result in better vision preservation and less frequent trips to the doctor. AiViva BioPharma AiViva BioPharma, a clinical-stage biotech company headquartered in Newport Beach, California, is developing AIV007 in combination with its JEL™ technology – a drug the company says has the potential to address the underlying root cause of vision loss from wet AMD and treat the disease with good clinical outcomes that preserve and enhance vision in patients while reducing visits to the doctor. How Is AiViva’s Drug Different? AiViva’s proprietary JEL™ technology allows for the placement of the drug directly at the site of disease, where it forms a depot for prolonged drug release. A unique feature of AiViva’s JEL™ is that its delivery medium is a liquid at room temperature, which upon injection into the diseased eye tissue at a warmer body temperature quickly hardens into a gelatin-like mass. This drug-infused mass (a drug depot) then serves as a storehouse to release the drug over time to the disease site, effectively preventing blood from leaking into the macula. In addition to stemming fluid or blood leaking, the company reports demonstrating proof of concept of AIV007’s potential to remove scarring within the macula which accounts for long-term vision loss and no current treatment addresses. AIV007 has a unique mechanism of action by targeting multiple key receptors VEGFR, PDGFR, and FGFR, and TGFβ1. These actions collectively and effectively address abnormal growth of leaky blood vessels, underlying inflammation and scarring. Other companies offering maintenance treatment for wet AMD include Ocular Therapeutix Inc. (NASDAQ: OCUL), Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), Clearside Biomedical Inc. (NASDAQ: CLSD), Aerie Pharmaceuticals Inc. (NASDAQ: AERI) and Graybug Vision Inc. (NASDAQ: GRAY). The company says that its distinct edge over the competition is its ability of specific drug delivery which currently available treatments do not offer - its precision medicine is advantageous to achieve long local drug action and no systemic toxicity. The characteristics of the JEL™ Technology also allow for the customization of drug-release profiles, easy administration by physicians, optimal drug exposure in target tissues and the development of indication-specific formulations. Owing to these advantageous properties of the drug, AiViva plans to adapt its JEL™ Technology for new treatments in urology, ophthalmology, and oncology. AiViva has a diverse pipeline focused on wet AMD, prostate disorders, scarring, and nonmelanoma skin cancer. It believes AiViva’s JEL™, formulated with suitable active compounds, could potentially be developed for the treatment of many other diseases, including solid tumors. The clinical trial for AIV007 intended for the treatment of wet AMD is expected to commence in 2023. AiViva believes that as far as the treatment of retinal diseases goes, AIV007 in its JEL™ form also could potentially be developed for the treatment of diabetic macular edema, retinal vein occlusion and diabetic retinopathy. An Experienced Team And Patent-Backed Products The company’s web profile highlights a leadership team of seasoned industry experts with a track record in successful drug development and commercialization, who, under the leadership of company President and CEO Diane Tang-Liu, have reportedly brought multiple successful products to the market through Food and Drug Administration (FDA) approval. AiViva boasts a diverse product pipeline it says is expected to address a large, combined market, potentially delivering a combined multibillion-dollar revenue. Its delivery technology and medical uses are protected by strong intellectual property positions with 23 issued product patents and over 40 patents pending worldwide. The company's founders have made multiple initial public offerings (IPOs) on the New York Stock Exchange and the Nasdaq Stock Exchange and a successful reverse merger. AiViva has raised over $30 million, including $10 million raised during 2022. AiViva was rated as a top 20 clinical-stage biopharma company by Life Sciences Review in 2022 and could be one to watch in the transformative treatments in ophthalmology space. Interested in investing in AiViva? Go here. AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ. The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information. Contact Details Shane Cerrato michael@aiviva.com Company Website https://aiviva.com/

November 15, 2022 03:41 PM Eastern Standard Time

Empower Clinics adds US healthcare executive to board of directors

Empower Clinics Inc.

Contact Details Proactive Proactive Studio +1 604-688-8158 action@proactiveinvestors.com Company Website https://www.proactiveinvestors.ca

November 15, 2022 11:35 AM Eastern Standard Time

Video

Can This Company’s Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?

SciSparc Ltd.

Learn More about SciSparc Ltd. by gaining access to the latest research report There is a high probability that you may know someone battling some form of addiction. Whether it’s a problem with opioids, alcohol, cocaine, or even using pain meds, an unchecked addiction can be fatal. Addiction, or substance use disorder (SUD), can be a chronic mental health condition that demands urgent attention before it gets out of hand. Take alcohol abuse, for example; the World Health Organization (WHO) estimates that three million deaths yearly result from the harmful use of alcohol. This represents 5.3% of all deaths. Overall, 5.1% of the global burden of disease and injury is attributable to alcohol, as measured in disability-adjusted life years (DALYs). Looking at the overall drug abuse and addiction globally, around 275 million people used drugs worldwide in 2020, while over 36 million people suffered from drug use disorders, according to the 2021 World Drug Report by the United Nations Office on Drugs and Crime (UNODC). Zooming into the U.S., the National Center for Drug Abuse Statistics (NCDAS) estimates that nearly half of all people 12 and older in the U.S. have used an illicit substance at least once. Since 2000, almost one million people have died of a drug overdose. These staggering statistics call for effective therapies and treatment centers to help curb the trend, especially as there are indications that the number of drug users worldwide is likely to climb up to 11% by 2030. Rising awareness about the adverse effects of alcohol and substance abuse, the introduction of new therapies, and increasing rehabilitation centers are expected to fuel the growth of the global substance abuse treatment market. The global substance abuse treatment market was valued at $10.2 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 8.5% from 2022 to 2031. The market is anticipated to cross $23.1 billion by 2031. Pharmaceutical companies like Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), Viatris Inc. (NASDAQ: VTRS), SciSparc Ltd. (NASDAQ: SPRC), and BioCorRx Inc. (OTCMKTS: BICX) are advancing research and therapies aimed at serving the needs of the market. SciSparc is a specialty clinical-stage pharmaceutical company focused on developing therapies to treat CNS disorders from a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on tetrahydrocannabinol (THC) and nonpsychoactive cannabidiol (CBD). The company’s pipeline of product candidates includes SCI-110 for treating Tourette syndrome, Alzheimer’s disease and agitation; SCI-160 for treating pain; and SCI-210 for treating autism spectrum disorder and status epilepticus. It also has CannAmide™, an immediate unique palmitoylethanolamide (PEA) oral formulation for reducing chronic pain and inflammation. Positive Results For Psychedelic Combination Treatment In May this year, SciSparc announced positive efficacy and safety profile results from its joint preclinical trial with Clearmind Medicine Inc. (NASDAQ:CMND,CSE: CMND)), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems. The trial tested the proprietary combination of SciSparc’s CannAmide™ with Clearmind’s psychedelic molecule5-Methoxy-2aminoindane ( MEAI ) for suppressing alcohol use disorder. A histopathology assessment was conducted on several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen and thyroid gland) from all experiment groups to determine the safety of the proprietary combination of MEAI and CannAmide™ versus control mice that were not exposed to alcohol. Previously announced successful results showed a significant dose-dependent effect for the MEAI treatment in reducing alcohol consumption in treated animals, with substantial additional effect when combining CannAmide™ with the lower sub-effective MEAI dose. On Aug. 24, the company announced additional positive preclinical results of its psychedelic-based pharma collaboration for treating cocaine addiction using MEAI. These preclinical study results add to the company’s collaboration with Clearmind for its combination treatment for various addictions, including preclinical studies results and filing two provisional patent applications related to compositions comprising MEAI and n-acylethanolamines, their use and treating cocaine addiction. Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel led a preclinical trial designed to evaluate the possible reward-like effects of MEAI in connection to cocaine and its ability to abolish cocaine- induced conditioned place preference. The self-administration paradigm, the gold-standard model for examining drug addiction, was used in the preclinical trial. Rats were catheterized and trained to self-administer cocaine. The results identified a statistically significant sub-group that responded dramatically to the treatment, significantly decreasing the craving for cocaine compared to a nontreated control group. Follow the story at SciSparc’s website here. SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Christine Petraglia christine@tradigitalir.com Company Website https://scisparc.com/

November 15, 2022 10:25 AM Eastern Standard Time

Oxford Cannabinoid Technologies nearly ready for new phase 1 trial

Oxford Cannabinoid Technologies Holdings PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 15, 2022 10:22 AM Eastern Standard Time

Video

1 ... 191 192 193 194 195 ... 308